RxDoctor Payments Data

Jenny Simmons, PA

Physician Assistant · Bentonville, ARNPI 1164675518

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.8% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 45.0% of the total.

$4,825in general payments, 2019–2025

Across 298 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$548
  • Johnson & Johnson$438
  • LEO Pharma Inc.$335
  • Sun Pharmaceutical Industries Inc.$259
  • Sanofi$193
  • plus $881 from 15 others

What the payments were for

  • Food & beverage$4,62296%
  • Education$2034%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,825 in reported general payments places this provider in the 85th percentile of 451 physician assistant providers in Arkansas.

See all physician assistant providers in Arkansas

Medicare billing

Part B allowed, 2024
$78,888
Medicare patients
615
Services billed
2,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa45$851,556
Humira(Cf) PenAdalimumab18$213,839
Dupixent SyringeDupilumab52$186,935
Dupixent PenDupilumab33$113,746
Cosentyx Unoready PenSecukinumab13$87,857
OtezlaApremilast11$53,138
Clobetasol Propionate105$4,020
Ketoconazole158$2,824
Betamethasone Dipropionate40$2,159
Metronidazole23$1,566
Doxycycline Hyclate94$1,564
Fluocinonide28$1,288
Clindamycin Phosphate26$936
Tacrolimus13$892
Triamcinolone Acetonide79$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$45$53,13811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 451 physician assistant providers in Arkansas.

Other physician assistant in Bentonville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →